Clarivate Analytics Appoints Industry Veterans to Expand Thought Leadership and Strategy Team and Deliver a Path to Innovation
Team of experts will focus on research, analytics and insights surrounding key issues and challenges impacting the life sciences
LONDON, UK. May 8, 2019 — Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, announced today the appointment of Sarah Hardison, Ph.D., and Garth Ringheim, Ph.D., to the Company’s Life Sciences Strategy & Thought Leadership team.
The group will focus on driving industry discussion around two dynamic trends that are transforming the drug and medical device development landscape: disruptive innovation and R&D success and efficiency. Through independent research, as well as collaboration with other thought leaders and innovators, the newly formed team will explore the challenges and opportunities facing life sciences companies around the world as they grapple with these complex issues.
“A profound set of transformations is taking place across life sciences as scientific breakthroughs, advances in technology, global market expansion and pricing and market access issues are challenging the status quo,” explained Mukhtar Ahmed, President, Life Sciences at Clarivate Analytics. “These changes bring exciting opportunities. For example, disruptive technologies serve as catalyst for bold approaches to new medicines in immuno-oncology and translational medicine as well as the advancements that have emerged through digital health. Having a team dedicated to analyzing and providing insights on such disruptions will provide greater value to our clients and the industry overall, inevitably driving further innovation.”
Ringheim and Hardison join Clarivate as Therapeutic Area Directors, part of the company’s Strategy & Thought Leadership group led by Brandon Boyd. With a combined 40 plus years of life sciences experience, the newly-formed team of experts is poised to help address the challenges of research and development.
Prior to joining Clarivate, Hardison held product and portfolio management roles in life sciences reagents companies such as Abcam and Horizon Discovery, where she established a pipeline of research-use antibodies and developed a suite of preclinical screening services for immune-oncology biologics, respectively. Hardison earned her Ph.D. in Immunology at the University of Texas, followed by a postdoctoral fellowship at the University of Aberdeen.
Ringheim brings nearly 30 years of pharmaceutical and biotechnology industry experience to Clarivate, with deep expertise in bringing drug candidates from discovery research and development through to clinical trials and regulatory approvals at Sanofi and Celgene. His scientific involvement in FDA-approved therapeutics includes Areva (rheumatoid arthritis), Aubagio (multiple sclerosis) and Otezla (psoriasis and psoriatic arthritis). In addition to serving on scientific editorial boards and reviewer committees, Ringheim also served five years as chairperson for the Veterans Affairs Neurobiology D Unit in Washington, D.C. He earned his Ph.D. in Biochemistry from the University of California at San Diego.
As the Director of Strategy & Thought Leadership for Life Sciences at Clarivate, Boyd manages strategic initiatives that support offering development and guides the organization’s thought leadership engagement with the pharmaceutical, biotech and scientific communities. Previously, Boyd was Segment Lead for Generics at Clarivate, responsible for managing and developing the Newport product suite, the Company’s active ingredient and generic finished dose intelligence solution. Prior to joining Clarivate, Boyd held positions of increasing responsibility at Teva Pharmaceuticals, including Head of Market Insights for U.S. generics, where he led a team of research and analytics professionals charged with delivering business performance reporting and market intelligence. Boyd earned his MBA from the Pennsylvania State University.
Cortellis gives life to science by unlocking the hidden insights in data. As an industry-leading solution, Cortellis curates broad and deep sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation.
For more information, visit www.clarivate.com/products/cortellis/.
Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations.
For more information, please visit www.clarivate.com.
This press release and oral statements made with respect to information contained in this release may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.